Neoadjuvant Archives - Page 2 of 4 - Agendia

Neoadjuvant therapy

The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy

Publication: Annals of Surgical Oncology, Sept 1 2023 Authors: Peter Blumencranz MD, FACS, Mehran Habibi MD, Steve Shivers PhD, Geza Acs MD, Lisa E. Blumencranz PhD, Erin B. Yoder MS, Bastiaan van der Baan MS, Andrea R. Menicucci PhD, Patricia Dauer PhD, William Audeh MD & Charles E. Cox MD

Read More

Karen Guzdzial2024-02-16T06:56:48-08:00September 5th, 2023|Evidence, MINT, Neoadjuvant|

TRAIN 2 Trial: BluePrint predicts response to neoadjuvant pertuzumab in HER2-positive

Breast Cancer Research 25, Article Number: 71 (2023) Authors: Liefaard et al.

Read More

Karen Guzdzial2024-03-26T09:34:36-07:00June 26th, 2023|Evidence, HER2-positive, Neoadjuvant, Other, TRAIN2|

MammaPrint^® Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2 breast cancer in NBRST

Publication: ASCO 2023, Abstract #521 Authors: Peter D. Beitsch 1 , James V. Pellicane 2 , Lajos Pusztai 3 , Paul L. Baron 4 , Erin F. Cobain 5 , Mary K. Murray 6 , Andrew Ashikari 7 , Pond R. Kelemen 7 , Angela Marie Mislowsky 8 , Julie Barone 9 , Kenneth H. Cowan 10 , Rakhshanda Layeequr Rahman 11 , William C. Dooley 12 , Andrea Menicucci 13 , Christine Carruth 13 , M. William Audeh 13 , Pat W. Whitworth 14 , NBRST Investigators Group

Read More

Joel Adamich2024-02-16T06:58:05-08:00June 18th, 2023|Evidence, NBRST, Neoadjuvant|

ImPrint immune signature in 10,000 early stage breast cancer patients from FLEX Study

SABCS 2022, Poster ID: PD9-08 Authors: Brufsky et al.

Read More

Karen Guzdzial2024-03-28T12:50:31-07:00December 28th, 2022|Evidence, FLEX, Immunotherapy, Neoadjuvant, Other|

I-SPY2: ImPrint immune signature identifies ESBC patients who benefit from PD1 checkpoint inhibition

ASCO 2022, Poster #514 Authors: Kuilman et al.

Read More

Karen Guzdzial2024-03-28T14:32:52-07:00June 28th, 2022|Evidence, I-SPY2, Immunotherapy, Neoadjuvant, Other|

Durvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results

I-SPY2 Trial, Cancer Cell 39, 989–998, 2021 Authors: Pusztai et al.

Read More

Karen Guzdzial2024-03-27T10:14:11-07:00July 27th, 2021|Evidence, I-SPY2, Immunotherapy, Neoadjuvant, Other|

Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint

PUBLICATION: ASCO 2021 Authors Joyce O’Shaughnessy1, Virginia G. Read More

kevin2024-02-20T13:16:52-08:00July 7th, 2021|Evidence, FLEX, Neoadjuvant|

5-year distant metastasis-free survival outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial

Publication: St. Gallen Authors: E. Göker, M.P. Hendriks, M. van Read More

kevin2024-02-16T07:03:03-08:00March 17th, 2021|Evidence, NBRST, Neoadjuvant|

Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients

Publication: Miami Breast Authors Pat Whitworth, James Read More

kevin2024-03-07T10:51:13-08:00March 8th, 2021|Evidence, NBRST, Neoadjuvant|

MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer
Gallery
MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer

Adjuvant, Evidence, MINT, Neoadjuvant

MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer

PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Read More

kevin2024-03-25T08:05:58-07:00December 29th, 2020|Adjuvant, Evidence, MINT, Neoadjuvant|

Previous 123 Next

Agendia precision oncology

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.